“The first study was conducted in male and female monkeys once weekly for 5 weeks at doses of 0.1, 1, or 10 mg/kg IV infusion with a subsequent recovery period of 12.”
“As linvoseltamab is intended for use in patients with advanced malignancies, carcinogenicity studies were not conducted with linvoseltamab, consistent with ICH S9 guideline Nonclinical Evaluation of Anticancer Pharmaceuticals.”
No surrogate used; clinical molecule tested in cynomolgus monkey
“Safety pharmacology evaluations were integrated into a GLP-compliant repeat-dose toxicology study conducted in Cynomolgus monkeys using linvoseltamab”